ArticleDisease markers2015
Fatigue in patients with multiple sclerosis: is it related to pro- and anti-inflammatory cytokines?
Article in Disease markers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Trial
- Vertical saccadic slowing is associated with fatigue in multiple sclerosis.Fatigue : biomedicine, health & behavior · 2026Article
- Neurophysiological, imaging and neurobiological markers of central fatigue in multiple sclerosis.Brain communications · 2026Article
- Fatigue: a common but poorly understood symptom in neurological and non-neurological diseases.Nature reviews. Neurology · 2025Review
- Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis.Journal of neurology · 2025Article
- Interaction of the viral infectious agents in the development and exacerbation of the multiple sclerosis.Le infezioni in medicina · 2023Review
- Perception of Physical Demand, Mental Demand, and Performance: A Comparison of Two Voice Interventions for Parkinson's Disease.American journal of speech-language pathology · 2022Article
- Symptom Interconnectivity in Multiple Sclerosis: A Narrative Review of Potential Underlying Biological Disease Processes.Neurology and therapy · 2022Review
- Fatigue in Multiple Sclerosis Is Associated with Reduced Expression of Interleukin-10 and Worse Prospective Disease Activity.Biomedicines · 2022Article
- Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Review
- Article
- Altered in vivo brain GABA and glutamate levels are associated with multiple sclerosis central fatigue.European journal of radiology · 2021Article
- Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue-Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers.Biomolecules · 2021Article
- Exploring the roles of tryptophan metabolism in MS beyond neuroinflammation and neurodegeneration: A paradigm shift to neuropsychiatric symptoms.Brain, behavior, & immunity - health · 2021Review
- Co-occurrence of Fatigue and Depression in People With Multiple Sclerosis: A Mini-Review.Frontiers in neurology · 2021Review
- Non-restorative Sleep Caused by Autonomic and Electroencephalography Parameter Dysfunction Leads to Subjective Fatigue at Wake Time in Shift Workers.Frontiers in neurology · 2019Article
- The Role of Inflammation in Depression and Fatigue.Frontiers in immunology · 2019Review
- Fatigue after a first attack of suspected multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2018Article
- Is there a link between inflammation and fatigue in multiple sclerosis?Journal of inflammation research · 2018Review
- Salivary IL-1ß as an Objective Measure for Fatigue in Multiple Sclerosis?Frontiers in neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the pathophysiological role of pro- and anti-inflammatory cytokines in primary multiple sclerosis-related fatigue.
methodsFatigued and non-fatigued patients with multiple sclerosis (MS) were recruited and their cytokine profiles compared. Patients with secondary fatigue were excluded. Fatigue was assessed with the self-reported Checklist Individual Strength (CIS20r), subscale fatigue. A CIS20r fatigue cut-off score of 35 was applied to differentiate between non-fatigued (CIS20r fatigue ≤34) and fatigued (CIS20r fatigue ≥35) patients with MS. Blood was collected to determine the serum concentrations of pro-inflammatory cytokines (IL-1β, IL-2, IL-6, IL-8, IL-12p70, IL-17, TNFα, and IFN-γ) and anti-inflammatory cytokines (IL-4, IL-5, IL-10, and IL-13). We controlled for the confounding effect of age, gender, duration of MS, disease severity, type of MS, and use of immunomodulatory drugs.
resultsSimilar cytokine levels were observed between MS patients with (n = 21) and without fatigue (n = 14). Adjusted multiple regression analyses showed a single significant positive relationship, that of IL-6 with CIS20r fatigue score. The explained variance of the IL-6 model was 21.1%, once adjusted for the confounding effect of age.
conclusionThe pro-inflammatory cytokine interleukin-6 (IL-6) may play a role in the pathophysiology of primary fatigue in patients with MS. TRIAL REGISTRATIONS: ISRCTN69520623, ISRCTN58583714, and ISRCTN82353628.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.